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Abstract  27 
β-lactam resistance in methicillin-resistant Staphylococcus aureus (MRSA) is 28 
mediated by the expression of an alternative penicillin-binding protein 2a 29 
(PBP2a, encoded by mecA) with a low affinity for β-lactam antibiotics. 30 
Recently, a novel variant of mecA known as mecC was identified in MRSA 31 
isolates (mecC-MRSA) from both humans and animals. In this study, we 32 
demonstrate that the mecC encoded PBP2c does not mediate resistance to 33 
penicillin. Rather, broad-spectrum β-lactam resistance in mecC-MRSA strains 34 
is mediated by a combination of both PBP2c and the distinct β-lactamase 35 
encoded by blaZLGA251 which is part of the mecC-encoding SCCmec type XI. 36 
We further demonstrate that mecC-MRSA strains are susceptible to a 37 
combination of penicillin and the β-lactam inhibitor clavulanic acid in vitro, and 38 
that the same combination is effective in vivo for the treatment of an 39 
experimental mecC-MRSA infection in wax moth larvae. Thus we 40 
demonstrate how the distinct biological differences between the mecA and 41 
mecC encoded PBP2a/PBP2c has the potential to be exploited as a novel 42 
approach for the treatment of mecC-MRSA. 43 
 44 
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Introduction 52 
Antimicrobial resistance is a global health problem of particular importance, 53 
which has led to an urgent need for new antimicrobial drug development. An 54 
alternative approach to this problem is to re-sensitize resistant bacteria to 55 
existing antibiotics using novel inhibitors or synergistic combinations of 56 
existing drugs that overcome the mechanism(s) of resistance (1). The 57 
classical example of this is the combination of β-lactamase inhibitors such as 58 
clavulanic acid or sulbactams and a β-lactam antibiotic. Following the 59 
introduction of each generation of β-lactam, resistance has rapidly emerged. 60 
In the case of Staphylococcus aureus, penicillin resistance mediated by a 61 
blaZ encoded β-lactamase (penicillinase) was followed by the emergence of 62 
methicillin-resistant S. aureus (MRSA) shortly after the introduction of 63 
methicillin (a β-lactamase-resistant β-lactam) in 1961 (2, 3).  64 
 65 
Resistance to β-lactam antibiotics in MRSA is primarily mediated by the 66 
acquisition of an alternative penicillin-binding protein 2 (PBP2a) encoded by 67 
the mecA gene, which is carried on a mobile element known as a 68 
staphylococcal cassette chromosome (SCCmec) (4). In 2011, a new type of 69 
MRSA with a divergent mecA homologue known as mecC was described, 70 
which like some other types of MRSA is associated with livestock (5, 6). It has 71 
been demonstrated that mecC mediates resistance to cefoxitin and oxacillin in 72 
a range of strain backgrounds and that mecC expression is inducible with 73 
oxacillin (7). The mecC encoded PBP2a (PBP2c) shares only 63% amino acid 74 
identity with the mecA encoded PBP2a (PBP2a). The difference in amino acid 75 
identity is reflected in the distinct biochemical properties of PBP2c whereby it 76 
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shows a greater affinity for oxacillin than for cefoxitin and is less stable at 77 
37°C (8). Furthermore, unlike PBP2a, PBP2c does not require the 78 
transglycosylase (TGase) activity of the native PBP2 for high level resistance, 79 
suggesting it may preferentially cooperate with an as yet unidentified 80 
monofunctional TGase (8).  81 
 82 
Here we report that the biological differences between PBP2a and PBP2c 83 
extend to the unexpected finding that PBP2c does not mediate resistance to 84 
penicillin, and that expression of the β-lactamase – blaZ (blaZLGA251) located 85 
adjacent to mecC on the SCCmec type XI element is required for broad-86 
spectrum resistance to β-lactams. We demonstrate that this singular property 87 
of PBP2c can be exploited therapeutically for the treatment of mecC-MRSA 88 
infections.  89 
 90 
 91 
 92 
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Materials and methods 102 
Media and culture conditions 103 
Bacterial strains and plasmids used in this study are described in Table S5. 104 
For routine culture, Escherichia coli was grown in Lysogeny broth (LB) or on 105 
L-agar (Oxoid, UK) at 37°C. S. aureus was grown on tryptone soy agar (TSA), 106 
Columbia blood agar or in tryptone soy broth (TSB) or (Oxoid, UK) at 28°C or 107 
37°C accordingly. E. coli and S. aureus media were supplemented with 10 108 
µg/ml chloramphenicol (Cm10) as appropriate.  109 
 110 
Antimicrobial susceptibility testing  111 
Antimicrobial susceptibility testing was performed using disc diffusion 112 
susceptibility testing according to BSAC criteria (BSAC Methods for 113 
Antimicrobial Susceptibility Testing, version 13, June 2014). All antibiotic discs 114 
were purchased from Oxoid, UK. For the clavulanic acid assay, 15 µg/ml 115 
potassium clavulanate (Sigma-Aldrich, UK) was added to Iso-Sensitest agar 116 
(ISA) or Mueller-Hinton agar (MHA) (Oxoid, UK), as appropriate. Test isolates 117 
were grown to 0.5 McFarland standard in Iso-Sensitest broth (Oxoid, UK) and 118 
diluted 1:10 in distilled water before spreading onto agar plates with or without 119 
potassium clavulanate. After applying the antibiotic discs to Iso-Sensitest agar 120 
or Mueller-Hinton agar with 2% NaCl as appropriate, all plates were incubated 121 
at 35°C for 20 hours before inhibition zones were measured. Microbroth 122 
dilution for Minimum inhibitory concentrations (MIC) was performed according 123 
to BSAC (9). The range for MIC determination was 0.015-128 µg/ml for 124 
penicillin and 1-32 µg/ml for cefoxitin. For mecC/blaZ complemented strains, 125 
Iso-Sensitest broth was supplemented with anhydrotetracycline  (Atc) 200 126 
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ng/ml to induce expression of mecC/blaZ from pXB01, a modified tetracycline-127 
inducible expression vector pRMC2. 128 
 129 
Construction of S. aureus gene deletion mutants 130 
Oligonucleotide primer sequences are listed in Table S5. Using primer de-131 
blaF and de-blaR, inverse PCR was performed on pRMC2 using KOD Hot 132 
Start DNA Polymerase (Merck, UK) following manufacturers instructions to 133 
simultaneously remove the resistance gene bla and to introduce a NotI 134 
restriction site at each end of the PCR product. After NotI digestion and self-135 
ligation, a modified tetracycline-inducible expression vector was obtained, 136 
designated pXB01. mecC and blaZ deletion mutants in mecC-MRSA strains 137 
were generated by allelic exchange with the temperature-sensitive vector 138 
pIMAY, as described previously (10). Upstream sequence (AB) and 139 
downstream sequence (CD) of the S. aureus gene to be deleted were 140 
amplified with primers A/B or C/D using KOD Hot Start DNA Polymerase 141 
(Merck, UK). PCR products AB and CD were mixed in a single PCR fused by 142 
in splicing overlap extension (SOE) PCR using KOD Hot Start DNA 143 
Polymerase (Merck, UK) and using primers A/D to obtain deletion construct 144 
AD. Product AD was digested with restriction enzymes KpnI and SacI and 145 
ligated to pIMAY digested with the same enzymes. The resulting plasmids 146 
were designated pIMAYΔmecC or pIMAYΔblaZ. The plasmids were 147 
transformed into E. coli DC10B (a dcm deletion mutant of DH10B, allowing 148 
the plasmid to be directly transferred into S. aureus strains (10). Plasmid DNA 149 
extracted from DC10B was then electroporated into recipient strains to create 150 
knockout mutants. mecC-blaZ double deletion mutants were generated by 151 
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deleting blaZ gene from mecC deletion mutants using plasmid 152 
pIMAYΔmecCΔblaZ.  153 
 154 
Complementation of mutant strains 155 
For complement expression of mecC and blaZ, the genes were cloned into 156 
expression plasmid pXB01, a derivate of tetracycline-inducible expression 157 
vector pRMC2 deleted bla gene (11). Both genes including their ribosome 158 
binding site were amplified from LGA251 genome DNA with primers mecC-F-159 
KpnI / mecC-R-SacI and blaZ-F-KpnI / blaZ-R-SacI. PCR products were 160 
digested with KpnI and SacI and ligated with the pXB01 vector cleaved with 161 
the same enzymes, generating plasmids pXB01-mecC and pXB01-blaZ. The 162 
plasmids were transformed into E. coli DC10B, and plasmid DNA then 163 
extracted and electroporated into mutant strains for complementation with 164 
expression induced with 200 ng/ml anhydrotetracycline (Sigma-Aldrich, UK). 165 
 166 
Wax moth larvae (Galleria mellonella) infection and treatment assay 167 
The wax moth larvae assay was based on that previously described by 168 
Desbois et al (12). Galleria mellonella larvae were purchased in bulk from a 169 
commercial supplier: Livefood Ltd, UK. Larvae were stored at 4°C upon arrival 170 
and kept at 37°C during the course of the assay. mecC-MRSA strains 171 
LGA251, 02.5099.D and 71277 were selected for evaluation of antimicrobial 172 
activities of penicillin and clavulanic acid in combination. Single bacterial 173 
colonies were picked to inoculate 5 ml of TSB, and cultures were grown 174 
overnight (~16 hours) at 37°C and 200 rpm. Cultures were then diluted 1:100 175 
into 5 ml of fresh TSB and grown for a further 4 hours at 37°C and 200 rpm. 176 
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Cultures were then centrifuged at 2,500g for 10 minutes, and pellets 177 
resuspended in sterile phosphate buffered saline (PBS) to an OD595 of 0.2, 178 
giving approximately 1.3 × 106 CFU (range: 1.1 – 1.4 x 106) in 10 µl . For each 179 
strain, six groups of G. mellonella (n=10 in each group) were injected with 10 180 
µl aliquots of resuspended culture between two posterior thoracic segments 181 
using a Tridak Stepper Pipette Dispenser (Dymax, UK). Groups of G. 182 
mellonella were treated by injection with 50 mg/kg vancomycin, 40 mg/kg 183 
cefoxitin, 20 mg/kg penicillin sodium salt, 20 mg/kg potassium clavulanate, 20 184 
mg/kg penicillin sodium salt combined with 20 mg/kg potassium clavulanate or 185 
PBS at 2, 24 and 48 hours after inoculation. The treatments were given blind 186 
and the treatment identities not revealed until the experiment was completed. 187 
Larvae were considered dead when they did not respond to touch to the head. 188 
The experiment was performed twice with almost identical results, results of 189 
one experiment are presented in the text (Fig. 5), and the results for the 190 
second are presented in Fig. S3. 191 
 192 
In vitro selection of penicillin resistance 193 
LGA251 and 02.5099.D were serially passaged for 40 days in sub-inhibitory 194 
concentrations of penicillin in the presence of 15 µg /ml clavulanic acid. 195 
Briefly, strains were grown on Columbia blood agar and four single colonies 196 
were used to make a 0.5 McFarland standard in Iso-Sensitest broth. This was 197 
diluted to final 1:200 dilution in 2 ml of Iso-Sensitest broth with range of 2-fold 198 
penicillin concentrations (0.03125 to 4 µg/ml) and a fixed concentration of 15 199 
µg/ml clavulanic acid. After incubation for 24 hours at 37°C with 200 rpm 200 
shaking, the culture with the highest antibiotic concentration showing clear 201 
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visible growth was adjusted back to 0.5 McFarland standard and used to 202 
inoculate a fresh set of tubes as above and incubated for another 24 hours. 203 
Once growth occurred at the 4 µg/ml concentration of penicillin, the increment 204 
was changed from 2 fold increases to 2 µg /ml increases. At selected time 205 
points, cultures were plated out and 2 - 3 resistant colonies were picked, 206 
penicillin and cefoxitin MIC determined and the mecC gene amplified by PCR 207 
using primers mecCf:, mecCm and mecCr and sequenced (Source 208 
Bioscience Sequencing, Cambridge, UK) (Table S5). Strains LGA251ΔblaZ 209 
and 02.5099.DΔblaZ were also serially passaged for 40 days in sub-inhibitory 210 
concentrations of penicillin in the same manner but in the absent of clavulanic 211 
acid.  212 
 213 
Bioinformatics analysis  214 
β-lactamase sequences for type A (accession: EVL36279), B (accession: 215 
WP_020978264), C (accession: WP_015056218) and D (accession: Q53699) 216 
were downloaded from the NCBI. Alignments were generated using Muscle in 217 
Seaview (13, 14). For the phylogeny, blaZ from Macrococcus caseolyticus 218 
(accession: WP_041636568) was included as an outgroup and blaZ from 219 
Staphylococcus xylosus (accession: CCM44120) was included for comparison 220 
(15). Maximum likelihood phylogenetic trees were constructed using PhyML 221 
v3.0 in Seaview with a WAG substitution model and 100 bootstrap replicates 222 
(16). 223 
 224 
 225 
 226 
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Results  227 
PBP2c does not mediate resistance to penicillin 228 
Previously work by Kim et al. identified that the PBP2a encoded by mecC 229 
(PBP2c) had a higher relative affinity for oxacillin compared to cefoxitin, 230 
suggesting that PBP2c has a higher affinity for penicillins than cephalosporins 231 
(8). The class E mec complex (mecI–mecR1–mecC–blaZ) present in the 232 
SCCmec type XI contains a blaZ gene (henceforth: blaZLGA251) present 233 
downstream of the mecC gene. The blaZLGA251 is phylogenetically distinct from 234 
other previously reported blaZ genes in S. aureus (Fig. 1A) and mecC-MRSA 235 
strains with blaZLGA251 don’t harbor any other blaZ genes (data not shown). 236 
Currently there are four types (A to D) of staphylococcal β-lactamases based 237 
on the differences of amino acids at positions 128 and 216 (17, 18). At 238 
position 216, blaZLGA251 shares a serine with type A and D blaZ (Fig. 1B), 239 
while at position 128 blaZLGA251 uniquely has a leucine. Therefore, we propose 240 
that blaZLGA251 is a new staphylococcal blaZ type; a type E blaZ (Fig. 1).  241 
 242 
As PBP2c encodes low-level resistance to penicillins such as oxacillin and the 243 
SCCmec type XI mec complex included a novel type of blaZ, we investigated 244 
the relative contribution of mecC and blaZLGA251 to β-lactam resistance. We 245 
generated gene deletions of mecC, blaZ and both mecC/blaZ in two different 246 
mecC-MRSA strains; LGA251, a multilocus sequence type (ST)425 isolated 247 
from cattle in England and 02.5099.D, a ST1944 (CC130) isolate from human 248 
infection in Scotland (5). Deletion of mecC in LGA251 (LGA251∆mecC) and 249 
02.5099.D (02.5099.D∆mecC) caused loss of resistance to cefoxitin as 250 
measured by disc diffusion and MIC, while complementation with mecC 251 
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restored resistance as previously reported (Fig. 2A and Table S1) (7). 252 
However, deletion of mecC caused no reduction in penicillin resistance in 253 
either LGA251 or 02.5099.D, demonstrating that mecC did not mediate 254 
resistance to penicillin in either strain background (Fig. 2B and Table S1). In 255 
contrast when the blaZLGA251 gene was deleted, resistance to penicillin was 256 
abolished in both strain backgrounds and the penicillin MIC decreased from 8 257 
to <0.0075 and 32 to 0.0625 µg/ml in LGA251 and 02.5099.D, respectively 258 
(Fig. 2B and Table S1). Complementation of the mutants with blaZ restored 259 
penicillin MICs to wildtype levels in both backgrounds (Fig. 2B and Table S1). 260 
These findings were confirmed by the creation of double mecC/blaZ deletion 261 
strains (LGA251∆mecC∆blaZ) and (02.5099.D∆mecC∆blaZ), which were then 262 
individually complemented with plasmid-borne copies of mecC and blaZ. In 263 
each case it was the complementation with blaZ and not the complementation 264 
with mecC that restored resistance to penicillin (Fig. 2B and Table S1). 265 
 266 
mecC-MRSA strains are susceptible to a combination of clavulanic acid 267 
and penicillin in vitro 268 
As penicillin resistance in mecC-MRSA strains is mediated by the blaZLGA251 269 
alone, we tested if mecC-MRSA strains were susceptible to the combination 270 
of penicillin and clavulanic acid (a β-lactamase inhibitor). We included 271 
clavulanic acid at a clinically relevant concentration of 15 µg/ml in 272 
bacteriological media and carried out penicillin and cefoxitin disc diffusion 273 
assays according to BSAC criteria, against a panel of 30 mecC-MRSA 274 
isolates (Fig. 3) (19, 20). This showed that clavulanic acid increased 275 
susceptibility to penicillin in all strains tested (except strain Sa09315 which 276 
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was already susceptible due to a frameshift in blaZ) and more than doubled 277 
the mean zone of inhibition (10 cf. 27 mm – resistance cut off = 24 mm) (Fig. 278 
3). Furthermore, clavulanic acid reduced the penicillin MICs by a mean of 65-279 
fold and restored breakpoint susceptibility in 24 of 30 strains tested (Fig. 3A). 280 
In the remaining 6, the MIC was reduced to the breakpoint (breakpoint 0.12 281 
μg/ml) (Fig. 3A). In contrast, only minor reductions were seen for cefoxitin 282 
when combined with clavulanic acid (Fig. 3B). In view of the relative instability 283 
of PBP2c at higher temperatures (the assays were performed at 35ºC), we 284 
confirmed the effect of clavulanic acid on cefoxitin and penicillin at 25, 30 and 285 
37ºC. The results for cefoxitin showed a clear increase in the zone of 286 
inhibition with increasing temperature, as previously reported, with no major 287 
effect of clavulanic acid seen at any temperature (8) (Fig. S1). While for 288 
penicillin there was only a minor effect with increasing temperature and similar 289 
zones of inhibition in the presence and absence of clavulanic acid (Fig. S1). 290 
Together these data demonstrate that the effect of clavulanic acid was not 291 
due to the temperature-sensitive activity of PBP2c at 35ºC. 292 
 293 
Role of mecC and blaZ in resistance against a broad range of β-lactam 294 
antibiotics 295 
We next tested the effect of clavulanic acid on resistance against a broad 296 
range of β-lactam antibiotics (8 penicillins, 12 cephalosporins, 1 monobactam 297 
and 3 carbapenems) for the same panel of 30 mecC-MRSA strains. The 298 
results showed that clavulanic acid increased susceptibility to all penicillins 299 
tested except for oxacillin (Fig. 3C and Table S2). Oxacillin was tested on 300 
Mueller-Hinton agar as recommended by BSAC, EUCAST and CLSI 301 
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guidelines, and also using Iso-Sensitest where there was a small decrease in 302 
the presence of clavulanic acid (mean 20 cf. 24 mm), which was less than that 303 
observed for other penicillins. The effect of clavulanic acid was most 304 
pronounced for penicillin (mean 11 cf. 27 mm), amoxicillin (mean 22 cf. 34 305 
mm), ampicillin (mean 24 cf. 36 mm), and temocillin (mean 7 cf. 17 mm) (Fig. 306 
3 and Table S2). Only very small increases in susceptibility were seen in the 307 
presence of clavulanic acid for the tested cephalosporins and carbapenems, 308 
and no effect at all was seen for the one monobactam tested (aztreonam) 309 
(Fig. 3 and Table S2).  310 
 311 
To further understand the basis for the effect of clavulanic acid, we next 312 
tested the mecC/blaZ deletion mutant strains against the same range of β-313 
lactams in disc diffusions assays, alone and in the presence of 15 µg/ml 314 
clavulanic acid (Table S1). The results showed that the effect of clavulanic 315 
acid on penicillin resistance was negated in both the LGA251ΔblaZ and 316 
02.5099.DΔblaZ, indicating that, as would be expected, the zone increases 317 
mediated by clavulanic acid were dependent on the blaZLGA251 encoded β-318 
lactamase (Table S1). Interestingly, the presence of clavulanic acid alone in 319 
the media prevented growth of both the ΔmecC strains. Furthermore 320 
complementation with mecC on a plasmid failed to reverse this, nor was this 321 
effect seen in either of the ΔblaZ strains (LGA251ΔblaZ and 02.5099.DΔblaZ) 322 
demonstrating that it was not a by-product of the mutant construction process 323 
per se but most likely due to the specific loss of the chromosomally encoded 324 
mecC (Table S1).   325 
 326 
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Selection of penicillin resistance in mecC-MRSA isolates 327 
Next we sought to elucidate the molecular basis for why PBP2c was unable to 328 
mediate resistance to penicillin. We first attempted to identify mecC mutations 329 
that conferred resistance to penicillin by screening a collection of whole 330 
genome sequenced mecC-MRSA isolates (data not shown) to identify 331 
naturally occurring amino acid substitutions. We identified ten different amino 332 
acid substitutions present in PBP2c and tested representative isolates by 333 
penicillin disc diffusion with clavulanic acid to see if there was any effect on 334 
penicillin susceptibility (Table 1). None of the isolates tested showed any 335 
resistance to the combination of penicillin and clavulanic acid. We next sought 336 
to select mutants in vitro with PBP2c mutations conferring penicillin 337 
resistance. We grew two wildtype mecC-MRSA strains: LGA251 and 338 
02.5099.D in gradually increasing concentrations of penicillin supplemented 339 
with clavulanic acid at 15 µg/ml for forty days (Fig. 4). We also grew the 340 
corresponding isogenic ΔblaZ mutants (LGA251ΔblaZ and 02.5099.DΔblaZ) 341 
in penicillin alone  (Fig. 4). At a number of points in the experiment, isolates 342 
were plated to single colonies and 2-3 individual colonies tested for penicillin 343 
and cefoxitin MIC and mecC sequenced to identify potential mutations 344 
mediating penicillin resistance (Fig. 4). The MIC testing of LGA251ΔblaZ from 345 
day 9 and 02.5099.DΔblaZ from day 13 showed that as well as becoming 346 
penicillin resistant the strains had also substantially increased their resistance 347 
to cefoxitin (8 cf. ≥ 128 μg/ml), suggesting the change seen was a general 348 
increase in β-lactam resistance and not specific to penicillin (Table S3). Only 349 
colonies from wild-type strain 02.5099D grown in penicillin and clavulanic acid 350 
at day 40 (02.5099-D40-A) revealed the presence of G to A mutation at 351 
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position 1636 in mecC causing a Val546Ile substitution in the transpeptidase 352 
domain in PBP2c. None of the other strains screened had any mecC 353 
mutations, suggesting resistance was due to mutations elsewhere in the 354 
chromosome or upregulation of genes involved in resistance. Disc diffusion 355 
testing of two individual colonies (02.5099-D40-A-C1 and 02.5099-D40-A-C2) 356 
with the Val546Ile substitution showed that resistance had increased to all β-357 
lactam antibiotics except for aztreonam, which the strains were already 358 
completely resistant, and to ceftaroline, the new anti-MRSA cephalosporin 359 
(Table S4). We cloned the mutated mecC gene (mecCVal546Ile) from 02.5099-360 
D40-A-C1 and 02.5099-D40-A-C2 into RN4220 and into blaZ-mecC–null 361 
strains LGA251ΔblaZΔmecC and 02.5099.DΔblaZΔmecC and tested 362 
resistance to penicillin and cefoxitin using disc diffusion. We found that the 363 
strains with mecCVal546IIe were equally susceptible to penicillin as the wildtype 364 
mecC, demonstrating that the Val546Ile substitution alone was not capable of 365 
mediating resistance (Fig. S2A and Table S4). Interestingly however, when 366 
we tested the mecCVal546Ile strains for cefoxitin resistance, we found that the 367 
strains were not resistant to cefoxitin as measured by disc diffusion and had 368 
an MIC of 2 μg/ml in comparison to 16 μg/ml for strains expressing wildtype 369 
mecC (Fig. S2B and Table S4). Further disc diffusion testing against the full 370 
panel of ß-lactams, revealed that the Val546Ile substitution only effected 371 
resistance to cefoxitin (Table S4). This demonstrates the importance of valine 372 
at position 546 for specifically mediating cefoxitin resistance in PBP2c. 373 
 374 
 375 
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A combination of clavulanic acid and penicillin is effective in vivo for 376 
treatment of mecC-MRSA infections 377 
Finally, we sought to determine if the effect of penicillin and clavulanic acid 378 
seen in vitro could translate to therapeutic treatment of S. aureus infection in 379 
vivo. We used the wax moth larvae model of infection with 3 different mecC-380 
MRSA strains belonging to different multi-locus sequence types; LGA251 381 
(ST425), 02.5099.D (ST1944), 71277 (ST130) (12). We compared the effect 382 
of penicillin / clavulanic acid (2:1) with penicillin, clavulanic acid, cefoxitin and 383 
PBS against a gold standard treatment of vancomycin (Fig. 5). For both 384 
LGA251 and 02.5099.D 10% of larvae treated with PBS or clavulanic acid 385 
survived to 120 hours, while for 71277, larvae were all dead by 48 and 68 386 
hours, respectively (Fig. 5). Treatment with penicillin alone led to a modest 387 
improvement, with survival at 120 hours of 20% for LGA251, 30% in 388 
02.5099.D and 20% in 71277 (Fig. 5). Despite the presence of PBP2c, 389 
cefoxitin performed moderately better than penicillin and with survival at 120 390 
hours to 40% in LGA251 and 71277 and to 50% in 02.5099.D. In contrast, 391 
survival at 120 hours for penicillin and clavulanic acid was 90% for LGA251, 392 
65% for 71277 and 70% for 02.5099.D (Fig. 5). While the ‘gold standard’ 393 
treatment of vancomycin had survival at 120 hours of 90% for LGA251 and 394 
80% for, 02.5099.D and 71277, respectively (Fig. 5). Statistical analysis 395 
showed there was no significant difference between treatment with a 396 
combination of penicillin and clavulanic acid and vancomycin (Log-rank 397 
(Mantel-Cox) Test: LGA251; P = 0.970, 02.5099.D; P = 0.259, and 71277; P = 398 
0.370). Repeat experiments showed broadly identical results (Fig. S3). 399 
 400 
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Discussion 401 
Antibiotic resistance is major international problem and with few new 402 
antibiotics likely to be available in the immediate future. Novel methods to 403 
combat antibiotic resistance are therefore required, including repurposing 404 
older antibiotics. Here, we present evidence of one such case. We show that, 405 
the newly described mecC encoded PBP2c does not mediate resistance to 406 
penicillin and that the adjacently encoded type E blaZ gene is required for 407 
resistance to penicillin. Our data suggest that this biological difference can be 408 
exploited for treatment by combining penicillin and clavulanic acid, a β-lactam 409 
inhibitor, to block the action of the blaZLGA251-encoded β-lactamase. 410 
Importantly, we show that our in vitro data translate to successful treatment of 411 
experimental infections in vivo in a non-vertebrate model. The combination of 412 
penicillin and clavulanic acid was as effective as vancomycin in reducing the 413 
mortality of wax moth larvae infected with three different mecC-MRSA strains. 414 
We also observe in vitro activity of clavulanic acid in combination with 415 
amoxicillin – a combination that is already commercially available as 416 
Augmentin – suggesting that drugs already in clinical use might be successful 417 
in treating mecC-MRSA infections. Additionally, variable resistance to different 418 
cephalosporins has been reported previously for mecC-MRSA isolates, 419 
suggesting that certain cephalosporins might also be also be used for 420 
treatment (21). Our data for thirty mecC-MRSA isolates found uniform zones 421 
of inhibition (Fig. 3C) for all the cephalosporins tested, including susceptibility 422 
to ceftaroline (the new anti-MRSA cephalosporin). However given the reliance 423 
of cefoxitin/oxacillin testing for MRSA detection there is a lack of clinical 424 
breakpoints for most cephalosporins, therefore it is not clear if these zones of 425 
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inhibition would translate into clinical efficacy, further work is required to 426 
address this question.  427 
 428 
These findings suggest that penicillin can readily bind to PBP2c to prevent cell 429 
wall biosynthesis, a notion supported by data from Kim et al., which showed a 430 
higher binding affinity between the PBP2c to penicillins than cephalosporins in 431 
comparison to PBP2a (8). This is consistent with our finding that clavulanic 432 
acid was effective at conferring increased susceptibility against all the tested 433 
penicillins (except oxacillin) but had no effect against cephalosporins, It 434 
remains to be seen if this property is conserved amongst the variants of mecC 435 
identified in different coagulase negative staphylococci (15, 22-24). 436 
 437 
Biologically, the finding that the PBP2c has evolved so as not to mediate 438 
resistance to penicillin is of interest. The linkage of both mecC and blaZLGA251 439 
on a single genetic element might have enabled PBP2c to evolve distinct 440 
properties from PBP2a, without the constraint of having to mediate resistance 441 
to penicillin. This might suggest that the selective pressure to mediate 442 
resistance to cephalosporins or as yet unidentified β-lactam(s) under specific 443 
conditions (temperature, pH, ion concentration, etc) has selected PBP2c to be 444 
unable to mediate resistance to penicillin. Indeed, the previous demonstration 445 
that PBP2c is unstable at 37º, suggests that selection pressures might have 446 
selected for function at lower temperatures (8). Equally, it is known that there 447 
are specific fitness costs associated with expression of PBP2a including a loss 448 
of toxicity and later biofilm formation, and that high level ß-lactam resistance 449 
requires epistatic mutations (25-28). It remains to be seen what the distinct 450 
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advantage of the PBP2c is in comparison to PBP2a or the selective pressures 451 
that have driven this. 452 
 453 
mecC-MRSA strains are commonly isolated from cattle (29), and it is possible 454 
that the routine use of both 1st and 3rd generation cephalosporins for the 455 
treatment and prevention of mastitis may have provided the selective 456 
pressure that has driven the emergence of mecC-MRSA in dairy cows (30). 457 
Future studies should be targeted to investigate this question to provide 458 
insight for improvements in antibiotic stewardship in veterinary medicine. 459 
We have also identified the first mutation associated with specific loss of 460 
cefoxitin resistance in PBP2c. Comparison of PBP2c and PBP2a structures 461 
suggests this substitution might effect lobe:lobe positioning; also, V546 is 462 
adjacent to a beta strand “cascade” that likely packs differently in 463 
PBP2c/PBP2a protein cores i.e. V546(c)/L549(a) sits adjacent to 464 
I354(c)/L357(a) which could propagate all the way up to motif III (KSG) and 465 
motif I (SXXK) at active site (Fig. S4) (31, 32). Further structural insights into 466 
the difference between two proteins are required to shed further light on our 467 
understanding of the distinct biological properties of PBP2a and PBP2c. 468 
 469 
In conclusion, our findings further highlight how the limited functional 470 
sequence space can be exploited for antibiotic drug design and synergistic 471 
therapy. This is particularly important given the increasing challenges posed 472 
by multidrug resistance and offers a paradigm for tackling an emerging, 473 
resistant bacterial pathogen with an old antibiotic. 474 
 475 
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Table 1: Locations of amino acid substitutions in PBP2c in wildtype strains 635 
0820 ‘A’ to 51618 and the location of the substitution found in strain 02.5099-636 
D40-A. Residues likely in the transpeptidase domain (residues 324-665) 637 
based on alignment with PBP2a are highlighted in blue. 638 
Representative 
strain 
No. of 
isolates 
tested 
Position of amino acid substitution 
 63 130 145 173 185 269 346 349 466 482 546
LGA251 1 N V K N R Y A P R D V 
0820 'A' 1       S     
52902 2          N  
ST20120827 1   I         
77964 9    K        
Sa13307 4 K           
M4A 1        A    
71957 14         H   
m-40-71 1     L       
1198/2006 1  I          
51618 1      C      
02.5099-D40-A 1           I
 639 
 640 
 641 
 642 
 643 
 644 
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 647 
Figure legends  648 
Figure 1. (A) Maximum likelihood tree generated from amino acid sequences 649 
showing relationships of staphylococcal β-lactamases. Values above 650 
branches indicate bootstrap support. (B) Alignment of the amino acid 651 
sequence of representative type A-D β-lactamases in comparison to the 652 
SCCmec type XI encoded type-E (LGA251) β-lactamase. Highlighted 653 
residues indicate the amino acids at positions 128 and 216 used to type the β-654 
lactamase. 655 
 656 
Figure 2: Effect of deletion of mecC and blaZ in strains LGA251 and 657 
02.5099.D on the minimum inhibitory concentrations of: (A) cefoxitin; (B) 658 
penicillin. For each strain background (LGA251 and 02.5099.D) the first strain 659 
is the wildtype followed to the right by its various mutants and complemented 660 
mutants. +p denotes complemented with the empty vector, +pmecC 661 
complemented with a vector borne copy of mecC, +pblaZ with a vector borne 662 
copy of blaZ. 663 
 664 
Figure 3: The effect of clavulanic acid on mecC-MRSA strains. (A) 665 
Penicillin MICs (B) and Cefoxitin MICs for individual isolates in the presence 666 
(in red) and absence (in black) of clavulanic acid (C) Mean results for a panel 667 
of 30 mecC-MRSA strains against a range of β-lactam antibiotics as 668 
measured by disc diffusion assays in the presence and absence of clavulanic 669 
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acid. The error bars represent the standard error. Two and three letter codes 670 
and concentrations of discs are shown below each class of β-lactam 671 
antibiotics. Note: results are shown for oxacillin on two different media; Iso-672 
Sensitest and Mueller-Hinton agar with 2% NaCl at 30ºC (BSAC / June / 2014 673 
– recommended media). Resistance breakpoints for penicillin, oxacillin, 674 
cefoxitin are 24 mm, 14 mm, 21 mm, respectively). BSAC MIC breakpoint for 675 
penicillin (Pen) and cefoxitin (Fox) are 0.12 and 4 µg/ml, respectively. 676 
Clavulanic acid was included in the media at 15 µg/ml.  677 
 678 
Figure 4. In vitro selection of penicillin-resistance. Graphs show changes in 679 
subinhibitory concentrations for mutant mecC-MRSA strains LGA251ΔblaZ 680 
and 02.5099.DΔblaZ (A) or wild type mecC-MRSA strains LGA251 and 681 
02.5099.D (B) during the course of in vitro penicillin resistance selection (A) or 682 
penicillin and clavulanic acid selection (B) grown in continuous culture of Iso-683 
Sensitest broth at 37oC. Arrows indicates time points selected for mecC gene 684 
sequencing. 685 
 686 
Figure 5: Experimental treatment of Galleria mellonella infected by 687 
mecC-MRSA strains: (A) LGA251 (B) 02.5099.D (C) 71277.10. Ten larvae 688 
in each group were experimentally infected and then treated at 2, 24 and 48 689 
hours with Vancomycin (50 mg/kg / 6.73 x 10-9 mol), Penicillin (20 mg/kg / 690 
1.12 x 10-8 mol), Clavulanic acid (20 mg/kg / 1.69 x 10-8 mol), Penicillin / 691 
Clavulanic acid, Cefoxitin (40 mg/kg / 1.78 x 10-8 mol), and PBS alone. Figure 692 
shows data from a single experiment. 693 





